Table 1.

The clinical characteristics of patients with NK/T-cell lymphoma.

Parameters (No., %)	PD-L1+ monocytes in blood [%, median (range)]	P-value	PD-L1+ monocytes in tumor [%, median (range)]	P-value
Overall (42, 100%)	44.9 (1.0–98.8)		13.3 (0–56.3)
Gender
Male (29, 69%)	39.4 (1.0–98.8)	0.362	11.7 (0–47.1)	0.355
Female (13, 31%)	66.1 (5.7–94.1)		13.6 (1.3–56.3)
Age
< 60 (28, 67%)	33.5 (1.0–94.7)	0.109	14.3 (0–55.7)	0.660
≥ 60 (14, 33%)	62.2 (6.0–98.8)		12.2 (0–56.3)
ECOG score
0–1 (37, 88%)	39.4 (1.0–98.8)	0.026	11.7 (0–55.7)	0.001
≥ 2 (5, 12%)	81.8 (48.1–94.7)		43.6 (29.6–56.3)
Ann Arbor stage
I–II (35, 83%)	34.4 (1.0–98.8)	0.007	11.1 (0–55.7)	< 0.001
III–IV (7, 17%)	81.8 (48.1–94.7)		39.1 (29.6–56.3)
B symptoms
No (29, 69%)	59.3 (2.4–98.8)	0.111	16.6 (0–56.3)	0.111
Yes (13, 31%)	23.3 (1.0–90.7)		7.5 (0–27.0)
LDH
Normal (33, 79%)	34.3 (1.0–98.8)	0.471	13.6 (0–56.3)	0.890
Elevated (9, 21%)	46.4 (18.9–94.7)		11.1 (1.5–49.8)
NKPI score
0–1 (30, 71%)	31.8 (1.0–94.6)	0.002	9.3 (0–47.1)	0.002
2–4 (12, 29%)	81.7 (12.9–98.8)		34.6 (0–56.3)
Treatment response
CR (22, 52%)	36.9 (2.8–94.7)	0.420	12.5 (0–49.8)	0.830
non-CR (20, 48%)	52.1 (1.0–98.8)		13.5 (0–56.3)
Disease progression
No (31, 74%)	23.4 (1.0–94.7)	< 0.001	6.7 (0–38.7)	< 0.001
Yes (11, 26%)	81.8 (34.4–98.8)		39.1 (13.3–56.3)

CR, complete remission; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NKPI, natural killer/T-cell lymphoma prognostic index.